Displaying drugs 11451 - 11475 of 11637 in total
Nanoparticle Epirubicin
Nanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma). It is a novel epirubicin drug-conjugated polymeric micelle.
Investigational
Matched Description: … It is a novel [epirubicin] drug-conjugated polymeric micelle. …
Razuprotafib
Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.[L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
Investigational
Matched Description: … Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting …
MVR-T3011
MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1 antibody.
Investigational
Matched Description: … MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding …
Baxdrostat
Baxdrostat is under investigation in clinical trial NCT06344104 (A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Asian Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension).
Investigational
Matched Description: … Baxdrostat is under investigation in clinical trial NCT06344104 (A Phase III Study to Investigate the …
Mequitazine
Mequitazine is a histamine H1 antagonist (antihistamine). It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory...
Experimental
Matched Description: … Mequitazine is a histamine H1 antagonist (antihistamine). …
L523S
According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) and when delivered following incorporation into an E1B-deleted adenovirus (Ad/L523S)." It has been investigated as a lung cancer vaccine.
Investigational
Matched Description: … [A175909] It has been investigated as a lung cancer vaccine. …
Sonpiretigene isteparvovec
Sonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy. Developed by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP). Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks.
Investigational
Matched Description: … [L46676] Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three …
Faropenem medoxomil
Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic faropenem. The prodrug form of faropenem offers dramatically improved oral bioavailability and leads to higher systemic concentrations of the drug. Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by...
Investigational
Matched Description: … Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation …
HGTV-43
HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.
Investigational
Matched Description: … HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company …
PDPSC18
PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
Investigational
9-(4-hydroxybutyl)-N2-phenylguanine
9-(4-hydroxybutyl)-N2-phenylguanine is a solid. This compound belongs to the hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. 9-(4-hydroxybutyl)-n2-phenylguanine is known to target thymidine kinase.
Experimental
Matched Description: … 9-(4-hydroxybutyl)-N2-phenylguanine is a solid. This compound belongs to the hypoxanthines. …
TAK-428
TAK-428 is a drug for treating diabetic neuropathy. It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.
Investigational
Matched Description: … TAK-428 is a drug for treating diabetic neuropathy. …
Phenoxypropazine
Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the hydrazine chemical class. It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.
Withdrawn
Matched Description: … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging …
GZ-389988
GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee).
Investigational
Matched Description: … clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a …
Lixmabegagene relduparvovec
Lixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1). It is under development for the treatment of GM1 gangliosidosis.
Experimental
Matched Description: … Lixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector …
Carphenazine
Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.
Withdrawn
INCB13739
INCB13739 is developed as a new treatment for type 2 diabetes.
It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes.
Investigational
Matched Description: … INCB13739 is developed as a new treatment for type 2 diabetes. …
CYT007-TNFQb
CYT007-TNFQb is an active immunization therapy that aims at
providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low
amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.
Investigational
Matched Description: … CYT007-TNFQb is an active immunization therapy that aims at
providing a novel treatment to people suffering …
N-(carboxycarbonyl)-D-phenylalanine
N-(carboxycarbonyl)-D-phenylalanine is a solid. This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. It targets the protein hypoxia-inducible factor 1-alpha inhibitor.
Experimental
Matched Description: … N-(carboxycarbonyl)-D-phenylalanine is a solid. …
Cetrelimab
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
Investigational
Matched Description: … Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics …
CSL324
CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.
Investigational
Matched Description: … CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia …
SynOV1.1
SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).
Investigational
Matched Description: … It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating …
Natural Killer Cell
Natural Killer (NK) cells originate and differentiate from hematopoietic stem cells through various signalling pathways involving cytokines and interleukins. These cells arise from CD34+ lymphoid progenitors and comprise 10-15% of all lymphocytes in human peripheral blood. Once completely differentiated, NK cells lack B (CD19-) and T(CD3-) lymphocyte markers and carry...
Investigational
Matched Description: … leukapheresis: a technique where immune cells are separated from red blood cells. ... The most standard and utilized source of NK cells is directly from the peripheral blood of a donor through ... stem cells (iPSCs) and human embryonic stem cells (HESCs) are also used to generate NK cells through a …
Olmutinib
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals . Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in...
Investigational
EPC2407
EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. These tumors
include the frequently occurring cancers of the lung,...
Investigational
Matched Description: … EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of …
Displaying drugs 11451 - 11475 of 11637 in total